Page last updated: 2024-11-06

medifoxamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Medifoxamine is a synthetic, non-selective α-adrenergic agonist. It was initially studied for its potential therapeutic use in the treatment of conditions like shock and hypotension. Medifoxamine is thought to exert its effects by stimulating α-adrenergic receptors, leading to vasoconstriction and an increase in blood pressure. However, due to its relatively short duration of action and potential side effects, it has not been widely used clinically. Research on medifoxamine has largely ceased, and its use has been superseded by other more effective and safer α-adrenergic agonists. However, its pharmacological properties and mechanisms of action continue to be of interest for researchers studying the α-adrenergic system and related diseases.'

medifoxamine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36109
CHEMBL ID85231
CHEBI ID135061
SCHEMBL ID49319
MeSH IDM0105224

Synonyms (38)

Synonym
CHEMBL85231
brn 2054310
n,n-dimethyl-2,2-diphenoxyethylamine
einecs 251-011-4
medifoxaminum [inn-latin]
medifoxamine [inn:dcf]
n,n-dimethyl-2,2-diphenoxyethanamine
medifoxamine
ethanamine, n,n-dimethyl-2,2-diphenoxy-
medifoxamina [inn-spanish]
(dimethylamino)acetaldehyde diphenyl acetal
acetaldehyde, (dimethylamino)-, diphenyl acetal
medifoxamine (inn)
D07341
32359-34-5
CHEBI:135061
kwu7c2a1nt ,
medifoxaminum
medifoxamina
unii-kwu7c2a1nt
AKOS017343460
SCHEMBL49319
medifoxamine [mart.]
medifoxamine [inn]
medifoxamine [who-dd]
medifoxamine [mi]
DTXSID80186078
mfcd00865432
n,n-dimethyl-2,2-diphenoxy-ethanamine
Q544834
FT-0742206
DB13219
1-[(tert-butyl)oxycarbonyl]-3-(4-chlorobenzyl)piperidine-3-carboxylicacid
MS-23630
HY-119468
(2,2-diphenoxyethyl)dimethylamine
EN300-18563740
CS-0068451

Research Excerpts

Overview

Medifoxamine is a monoamine reuptake inhibiting antidepressant drug. It is in clinical use in France and is undergoing clinical investigation elsewhere.

ExcerptReferenceRelevance
"Medifoxamine is a novel monoamine re-uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake. "( Ocular hypotensive effects of medifoxamine.
Saleh, S; Turner, P, 1992
)
2.01
"Medifoxamine is a monoamine reuptake inhibiting antidepressant drug. "( Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers.
Johnston, A; Saleh, S; Turner, P, 1990
)
3.16
"Medifoxamine is a new monoamine re-uptake inhibiting antidepressant drug. "( Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans.
Johnston, A; Saleh, S; Turner, P, 1990
)
1.98
"Medifoxamine is a new antidepressant drug which is in clinical use in France and is undergoing clinical investigation elsewhere. "( Tolerability and kinetics of intravenous medifoxamine in healthy volunteers.
Edeki, T; Johnston, A; Saleh, S; Turner, P, 1990
)
1.99
"Medifoxamine is a new investigational antidepressant drug. "( Spectrofluorimetric analysis and buccal absorption of medifoxamine.
Blackett, AN; Randhawa, MA; Turner, P, 1986
)
1.96

Pharmacokinetics

ExcerptReferenceRelevance
" Medifoxamine was well tolerated and exhibited a first order linear pharmacokinetic profile."( Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers.
Johnston, A; Saleh, S; Turner, P, 1990
)
2.63

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability of oral medifoxamine was 21%."( Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans.
Johnston, A; Saleh, S; Turner, P, 1990
)
0.8
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's8 (61.54)18.2507
2000's1 (7.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.33 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (18.75%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other11 (68.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]